Sign in

CIK 0001806952

  • Non-accelerated filer
  • Smaller reporting company

Lyell Immunopharma, Inc.

Sign in to watch
Ticker
LYEL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833006753
Phone
+1 650-695-0677
Business address
201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$49,999,983
in 2 filings
Open-market sales, last 90 days
$28,757
in 6 filings

Net +$49,971,226. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2022-06-08 Bishop Hans Edgar Director Grant or award · Option (right to buy) +65,000 65,000
2022-06-08 FRIEDMAN CATHY Director Grant or award · Option (right to buy) +65,000 65,000
2022-06-08 Klausner Richard Director Grant or award · Option (right to buy) +65,000 65,000
2022-03-16 Turner Heather D Chief General Counsel Grant or award · Option (right to buy) +300,000 300,000
2022-03-16 Newton Charles W. Chief Financial Officer Grant or award · Option (right to buy) +500,000 500,000
2022-03-16 Homans Elizabeth Chief Executive Officer Grant or award · Option (right to buy) +1,479,500 1,479,500
2022-03-16 Hill Stephen J. Chief Technical Ops. Officer Grant or award · Option (right to buy) +700,000 700,000
2022-02-23 Bishop Hans Edgar Director Exercise or conversion +993,428 $0.10 $99K 4,540,234
2022-02-23 Bishop Hans Edgar Director Exercise or conversion · Option (right to buy) −993,428 169,610
2022-02-11 Lee Gary K. Chief Scientific Officer Grant or award · Option (right to buy) +800,000 800,000
2021-12-14 FRIEDMAN CATHY Director Other disposition −3,765,842 0
2021-12-14 FRIEDMAN CATHY Director Other acquisition +218,722 236,370
2021-09-13 Homans Elizabeth Chief Executive Officer Grant or award · Option (right to buy) +1,370,469 1,370,469
2021-06-21 GLAXOSMITHKLINE PLC 10% owner Conversion +30,253,189 30,253,189
2021-06-21 GLAXOSMITHKLINE PLC 10% owner Conversion · Series AA Preferred Stock −30,253,189 0
2021-06-21 NELSEN ROBERT Director Conversion +18,206,358 18,206,358
2021-06-21 NELSEN ROBERT Director Conversion +18,206,358 18,206,358
2021-06-21 NELSEN ROBERT Director Conversion · Series A Convertible Preferred Stock −17,771,216 0
2021-06-21 NELSEN ROBERT Director Conversion · Series A Convertible Preferred Stock −17,771,216 0
2021-06-21 NELSEN ROBERT Director Conversion · Series C Convertible Preferred Stock −435,142 0

Page 10 of 11 · 214 trades